PRENET

What PRENET does

PRENET (legal entity Laboratoře lékařské genetiky s.r.o.) is a Czech private limited company founded in 2015 that operates an integrated women's-healthcare platform combining prenatal diagnostics, gynecology, and medical genetics under a single brand. The company runs two clinic locations — Pardubice (headquarters at Masarykovo náměstí 2667) and Prague Vysočany (opening 1 July 2026 via subsidiary COP plus s.r.o.) — supported by an in-house accredited cytogenetics and molecular genetics laboratory holding ČIA accreditation no. 8080 and ISO 15189 compliance. Clinical services span combined first-trimester screening, NIPT (outsourced to GenePlanet), detailed fetal morphology and 3D/4D ultrasound, fetal echocardiography, superconsultation examinations, CVS and amniocentesis, preventive gynecology, STD testing (seven tiers), and HPV vaccination.

The diagnostic offering is built on QF-PCR (24–48h results), aCGH microarray (100–500x higher resolution than karyotype), standard karyotyping, NGS-based hereditary cancer panels (CZECANCA — 226 genes; plus GYNEKO, GASTRO, DERMATO, HEMATO specialty panels), reproductive carrier screening (ReproScreen, 27 recessive diseases), and the branded GenScan® comprehensive genetic analysis product. A WebLIMS physician portal delivers real-time laboratory results to referring gynecologists across the Czech Republic, formalizing the B2B referral channel. The technology stack includes OpenLIMS (STAPRO) deployed since August 2022 for laboratory information management.

PRENET's revenue model is dual-track: insurance-covered services billed through seven contracted Czech public health insurance funds (VZP, ČPZP, OZP, ZPMV, VOZP, ZPŠ, RBP), and a substantial self-pay segment for premium diagnostics not covered by insurance (NIPT 3,700–37,600 CZK; CZECANCA 40,000 CZK; GenScan Complex 17,600 CZK; 3D/4D ultrasound 1,300 CZK). Go-to-market combines direct-to-consumer appointment booking (phone, online portal, Meta/Facebook advertising) with a sales-led B2B motion targeting referring physicians. Customers are predominantly pregnant women seeking prenatal screening and women seeking gynecological preventive care, with secondary segments in couples planning pregnancy and individuals with hereditary cancer risk. The leadership team is led by CEO Ing. Ondřej Michalovský and includes academic-grade specialists from FN Motol and FN Hradec Králové.

Name

PRENET

Legal name

Laboratoře lékařské genetiky s.r.o.

Website

https://prenet.cz

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

PRENET is a Czech integrated women's-healthcare provider operating prenatal diagnostics, gynecology, and an accredited medical genetics laboratory across its Pardubice headquarters and a new Prague clinic. It serves pregnant women, fertility patients, and hereditary cancer-risk individuals via insurance-covered and self-pay channels.

Ownership category

akta.pro rank

Product category

Prenatal Diagnostics and Medical Genetics

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Maternal-Fetal Medicine (High-Risk Pregnancy) Centers (HLAFAJAB)

Keywords

• Prenatal diagnostic services
• Medical genetics testing
• Gynecological care services
• NIPT prenatal screening
• Hereditary cancer screening

Headquarters

HQ city

Pardubice

HQ country

Czechia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Healthcare Services - Insurance Covered: Many examinations are covered by public health insurance (VZP, ČPZP, OZP, ZPMV, VOZP, ZPŠ, RBP). Genetic examinations require physician referral and are fully covered by insurance.
2. Self-Paying Patients (Samoplátci): Premium services and specialized tests not covered by insurance are paid directly by patients. Includes NIPT tests (3,700-37,600 CZK), detailed ultrasound screenings, optional photography/video, and preventive genetic tests.
3. Prenatal Diagnostics Package Services: Comprehensive prenatal screening packages combining ultrasound and laboratory tests offered as premium self-pay services

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

Core offering

PRENET MEDICAL operates two specialty clinics (Pardubice headquarters and Prague Vysočany, opening July 2026) that deliver integrated prenatal diagnostics, gynecology, and clinical medical genetics services. The portfolio spans first/second/third trimester ultrasound screening, NIPT processed through GenePlanet, invasive procedures (CVS and amniocentesis), preventive gynecological examinations, STD testing panels, HPV and pertussis vaccination, and a comprehensive genetic-testing catalog (QF-PCR, aCGH, karyotyping, ReproScreen carrier screening, CZECANCA hereditary cancer panel, BRCA1/2 screen, GenScan and various single-gene tests). All genetic work is performed in an in-house ISO 15189-aligned, ČIA-accredited cytogenetics and molecular genetics laboratory.

Product overview

PRENET MEDICAL is a unified healthcare platform providing integrated prenatal diagnostics, gynecology, and medical genetics services. The company operates two clinic locations (Pardubice and Prague-Vysočany) supported by an in-house accredited genetic laboratory. The product portfolio is organized across three core areas: (1) Prenatal Diagnostics — including combined first-trimester screening, NIPT (GenePlanet-processed), detailed fetal morphology ultrasounds including 3D/4D imaging, fetal cardiac assessment, super-consiliary examinations, third-trimester screening, CVS, amniocentesis, and pertussis vaccination; (2) Gynecology — preventive examinations, STD testing in seven variants (VAGINAL, BASIC, STANDARD, COMPLEX, PREMIUM, 2v1, 3v1), HPV, HIV, hepatitis, syphilis, herpes, and chlamydia diagnostics; and (3) Genetics — genetic consultation, QF-PCR, aCGH, karyotyping, ReproScreen carrier screening, BRCA1,2 Screen, GYNEKO/GASTRO/DERMATO/HEMATO oncogenetic panels, CZECANCA 226-gene hereditary cancer panel, single-gene tests (cystic fibrosis, Wilson disease, SMA, Fragile X, GJB2 deafness, SHOX, celiac HLA-DQ, lactose intolerance), CLL prognostic panel, thrombophilia, Y-chromosome microdeletions, and the GenScan® comprehensive genetic analysis brand. Supporting infrastructure includes the Weblims web portal for result sharing between the lab and referring physicians, and the OpenLIMS (STAPRO) laboratory system adopted in 2022. All three service areas are interconnected, with genetic laboratory results informing prenatal and gynecological care decisions under one roof.

Differentiator

Problem solved

Functional benefit

Products and services

• NIPT — Non-Invasive Prenatal Testing (Non-invasive prenatal test) Non-invasive prenatal test analyzing cell-free fetal DNA from maternal blood from week 10 of pregnancy. Available in six variants: NIPT Rh (3,700 CZK), NIPT PLUS (13,500 CZK), NIPT PRO (15,900 CZK), NIPT PREMIUM (37,600 CZK), NIPT TWINS BASIC (11,500 CZK), and NIPT TWINS PRO (15,900 CZK). Screens for common trisomies, sex chromosome aneuploidies, up to 92 deletion/duplication syndromes, and up to 202 monogenic diseases in the PREMIUM tier. Samples processed at GenePlanet laboratory.
• Combined First Trimester Screening (Kombinovaný screening v I. trimestru) First-trimester screening combining detailed ultrasound at 11+3 to 13+6 weeks with maternal blood biochemistry (PAPP-A, free-beta-hCG, PlGF) to assess the risk of fetal chromosomal abnormalities and preeclampsia. Detects approximately 90–95% of Down syndrome cases. Not covered by public health insurance; eligible for health insurance contribution fund support.
• Detailed Fetal Morphology Assessment — II. Trimester (Podrobné hodnocení morfologie plodu ve II. trimestru) Detailed second-trimester fetal morphology ultrasound at 20–22 weeks assessing all major organ systems and detecting approximately 90% of structural fetal anomalies. Includes fetal growth assessment, placental position, and amniotic fluid evaluation. Self-pay service.
• 3D/4D Fetal Ultrasound Imaging (3D/4D ultrazvukové zobrazení plodu) Advanced 3D/4D fetal ultrasound performed on Voluson Expert 22 high-end equipment between 20–30 weeks. Delivers three-dimensional static and real-time video visualization of the fetus and includes USB flash drive plus printed color photo. Priced at 1,300 CZK and not covered by public health insurance.
• Prenatal Fetal Cardiac Examination (Prenatální vyšetření srdce plodu) Specialized fetal cardiac ultrasound performed by pediatric cardiologists MUDr. Viktor Tomek and MUDr. Hana Černá from FN Motol's Dětské kardiocentrum. Detects 80–90% of congenital heart defects, optimally at 18–22 weeks of gestation.
• Super-consiliary Fetal Examination (Superkonziliární vyšetření plodu) Multidisciplinary specialist ultrasound examination for high-risk pregnancies combining detailed structural, functional, and genetic assessment of the fetus, including fetal neurosonography and 3D technology. Nominated by referring gynecologist; covered by public health insurance when referred.
• Third Trimester Ultrasound Screening (Ultrazvukový screening ve III. trimestru) Third-trimester ultrasound at 30–32 weeks assessing fetal growth, placental position, amniotic fluid volume, and including Doppler blood flow assessment. Evaluates placental function in cases of fetal growth restriction. Not covered by public health insurance in this comprehensive scope.
• Amniocentesis (Odběr plodové vody / Amniocentéza) Invasive prenatal diagnostic procedure obtaining amniotic fluid under ultrasound guidance from 15 weeks gestation. Enables full chromosomal analysis (QF-PCR, karyotype, aCGH) and genetic testing of fetal DNA. Initial results within 48 hours, complete results in 2–3 weeks. Covered by public health insurance.
• Chorionic Villus Sampling / CVS (Odběr choriových klků) Chorionic villus sampling performed between 10–14 weeks of pregnancy for early invasive prenatal genetic diagnosis. Provides placental tissue for comprehensive fetal genetic analysis. First results available at the I/II trimester transition. Covered by public health insurance.
• Pertussis Vaccination in Pregnancy (Očkování proti černému kašli v těhotenství) Tdap or Tdap/IPV vaccination administered between 27–36 weeks of pregnancy to protect newborns through transplacental transfer of maternal antibodies. Recommended in every pregnancy due to declining antibody levels. Self-pay service.
• Preventive Gynecological Examinations (Preventivní gynekologické prohlídky) Routine gynecological preventive examinations including cervical cytology, pelvic ultrasound, breast examination, and health consultation. Available at both Pardubice and Prague branches with online booking.
• STD Testing Panels (Sexuálně přenosné nemoci) Sexually transmitted infection testing in seven variants: STD VAGINAL (800 CZK), STD BASIC (1,250 CZK), STD STANDARD (1,700 CZK), STD COMPLEX (2,250 CZK), STD PREMIUM (2,950 CZK), STD PREMIUM 2v1 (4,450 CZK), and STD PREMIUM 3v1 (5,950 CZK). Covers HIV, syphilis, hepatitis, chlamydia, gonorrhea, Mycoplasma, Trichomonas, Ureaplasma, HPV, and HSV with 3–5 working-day turnaround and express 24-hour options.
• HPV Vaccination (Gardasil 9) HPV vaccination including administration of Gardasil 9 at 3,500 CZK self-pay, supporting cervical cancer prevention.
• Genetic Consultation (Genetická konzultace) Clinical genetic consultation combining patient and family history evaluation, physical examination, and laboratory testing to assess genetic disease risks across prenatal, reproductive, oncogenetic, and carrier scenarios. Covered by public health insurance with physician referral.
• QF-PCR Rapid Aneuploidy Detection Rapid molecular diagnostic method for detecting aneuploidies of chromosomes 13, 18, 21, X, and Y including Down, Edwards, Patau, Turner, Klinefelter, XXX, and XYY syndromes. Results available within 24–48 hours. First-tier prenatal screening method before aCGH.
• aCGH Chromosomal Microarray (Array komparativní genomická hybridizace) Chromosomal microarray detecting microdeletions and microduplications with 100–500x higher resolution than standard karyotyping. Identifies over 100 microdeletion/microduplication syndromes including DiGeorge, Prader-Willi/Angelman, and Cri du chat. Recommended as first-line prenatal genetic test per the Czech Medical Genetics Society (2019). Results in 2–4 weeks.
• Karyotyping (Vyšetření karyotypu) Standard cytogenetic analysis of all 46 chromosomes from peripheral blood, amniotic fluid, chorionic villi, fetal blood, or miscarriage tissue. Detects numerical and structural chromosomal abnormalities. Results in 3–4 weeks.
• ReproScreen Carrier Screening Panel Genetic carrier screening panel detecting heterozygosity for 27 common recessive diseases (cystic fibrosis, spinal muscular atrophy, phenylketonuria, nonsyndromic deafness, Smith-Lemli-Opitz, etc.), thrombophilia mutations, and male/female fertility-related genetic factors. Results in approximately 2 months.
• CZECANCA Hereditary Cancer NGS Panel Next-generation sequencing panel analyzing coding regions and adjacent intronic sequences of 226 genes associated with hereditary cancer syndromes. Covers breast/ovarian (BRCA1/2, PALB2, CHEK2), colorectal (MLH1, MSH2, MSH6, PMS2/Lynch), melanoma (CDKN2A, CDK4), pancreatic, hematologic, and other hereditary cancer predispositions. Priced at 40,000 CZK.
• BRCA1/2 Screen Targeted genetic test examining 34 most common BRCA1 and BRCA2 mutations in the Czech/European population (21 in BRCA1, 13 in BRCA2) to assess hereditary breast, ovarian, and prostate cancer risk. Priced at 3,000 CZK, results in 4–6 weeks. Available without prior genetic consultation for self-paying clients aged 18+.
• GYNEKO Oncogenetic Panel — Breast, Ovarian, Prostate Cancer Oncogenetic panel examining BRCA1, BRCA2, PALB2, and CHEK2 genes associated with hereditary breast, ovarian, and prostate cancer (HBOC syndrome). Part of the CZECANCA 226-gene hereditary cancer panel, covering family planning and relatives' cancer risk assessment.
• GASTRO Oncogenetic Panel — Colorectal and GI Cancer Genetic panel for hereditary colorectal cancer and gastrointestinal malignancies including Lynch syndrome (HNPCC) caused by MLH1, MSH2, MSH6, PMS2 mutations. Part of the CZECANCA panel. Lifelong CRC risk of 28–75% for men and 24–52% for women with Lynch syndrome.
• DERMATO Oncogenetic Panel — Melanoma, Pancreatic Cancer Genetic panel for familial melanoma and pancreatic cancer assessing CDKN2A and CDK4 gene mutations. CDKN2A mutation carriers face up to 60% lifetime melanoma risk and 11–17% pancreatic cancer risk. Part of the CZECANCA panel.
• HEMATO Oncogenetic Panel — Hematologic Malignancies Genetic panel for hematologic malignancy predisposition including RUNX1 (MDS/AML/T-ALL), CEBPA (AML), and GATA2 (MDS/AML) genes. Part of the CZECANCA 226-gene hereditary cancer panel. Results in approximately 3 months.
• CLL Prognostic Panel (Chronic Lymphocytic Leukemia) Comprehensive prognostic panel for chronic lymphocytic leukemia including IgVH mutation status, TP53 mutation analysis, and FISH-detected genomic aberrations (11q-, +12, 13q-, 17p-) that assess treatment eligibility and inform therapeutic decisions.
• GenScan® Comprehensive Genetic Analysis Comprehensive genetic analysis brand with two tiers: GenScan Complex (17,600 CZK) covering broad hereditary and lifestyle disease risks, pharmacogenetics, cardiovascular, oncologic, metabolic, immunologic, and reproductive predispositions; and GenScan Individual (8,800 CZK) allowing selection of 5 from 11 categories for personalized analysis. Results in 3–4 months.
• Predictive Familial Mutation Testing (Prediktivní testování familiárních mutací) Targeted genetic testing for known familial mutations previously identified in a family member. Asymptomatic individuals are tested only for the specific mutation to assess inherited disease risk and enable early preventive measures.
• Cystic Fibrosis Genetic Testing (Cystická fibróza) CFTR gene analysis detecting the 50 most common mutations causing cystic fibrosis, the most frequent autosomal recessive disease in the Czech population (carrier frequency ~1:34). Assesses reproductive risk for couples planning pregnancy.
• Wilson's Disease ATP7B Analysis (Wilsonova choroba) ATP7B gene analysis for Wilson's disease, a copper metabolism disorder causing hepatic and neurological damage. Over 200 mutations identified. Useful for siblings of affected patients and unclear cirrhosis cases under age 45.
• Smith-Lemli-Opitz Syndrome DHCR7 Analysis DHCR7 gene analysis for Smith-Lemli-Opitz syndrome, a cholesterol synthesis disorder causing growth retardation, intellectual disability, cleft palate, syndactyly, and congenital heart/kidney defects. Autosomal recessive; incidence ~1:10,000 in the Czech population.
• Spinal Muscular Atrophy (SMA) SMN1/SMN2 Analysis SMN1 and SMN2 gene deletion analysis by MLPA method for spinal muscular atrophy. Homozygous SMN1 exon 7 deletion accounts for ~95% of SMA cases. Carrier frequency in Czech population is approximately 1:37; disease incidence ~1:10,000.
• Fragile X Syndrome (FRAXA) FMR1 Analysis FMR1 gene analysis detecting CGG repeat expansions causing Fragile X syndrome. Detects premutations (55–200 repeats) associated with FXTAS (males) and POI (females), and full mutations (>200 repeats) causing Fragile X syndrome.
• Congenital Hearing Loss GJB2 Testing (Vrozená porucha sluchu) GJB2 (connexin 26) gene mutation screening for autosomal recessive nonsyndromic congenital hearing loss. Most common Czech mutation: 35delG (p.Gly12Valfs). Also part of gamete donor screening.
• SHOX Gene Deletion/Duplication Analysis SHOX gene deletion/duplication analysis for growth disorders including Léri-Weill dyschondrosteosis (heterozygous) and Langer mesomelic dysplasia (homozygous). Associated with short stature and Madelung deformity. Results in 3 weeks.
• Y-Chromosome Microdeletion Testing (Mikrodelece chromozomu Y) Molecular analysis of AZF (azoospermic factor) regions on chromosome Y, the second most common genetic cause of male infertility. Detects AZFa, AZFb, and AZFc deletions associated with oligozoospermia and azoospermia. Results within 2 weeks.
• Thrombophilia Mutation Testing (Trombofilní mutace) Genetic testing for Factor V Leiden and Factor II (prothrombin) mutations associated with increased thrombosis risk, pregnancy complications, and recurrent miscarriage. Heterozygous FV Leiden carriers have 5–10x elevated venous thrombosis risk.
• Gamete Donor Genetic Screening (Genetická vyšetření dárců gamet) Genetic screening panel for gamete donors including karyotype, cystic fibrosis (CFTR), spinal muscular atrophy (SMN1/SMN2), and congenital hearing loss (GJB2). Required for all donors at PRENET's reproductive genetics unit.
• Celiac Disease HLA-DQ2/DQ8 Typing (Celiakie) HLA-DQ2 and HLA-DQ8 genetic typing for celiac disease risk assessment and differential diagnosis. Approximately 95% of celiac patients carry HLA-DQ2 and 5% carry HLA-DQ8. Negative result practically excludes celiac disease diagnosis. Prevalence in Czech Republic: 1:200 to 1:250.
• Lactose Intolerance LCT Testing (Laktózová intolerance) LCT gene polymorphism analysis (C/T-13910 and G/A-22018) determining lactase persistence versus non-persistence in adults. Approximately 36% of the Caucasian population is affected. Results in 2 weeks.
• Weblims Physician Result Portal Web-based laboratory information management portal (https://weblims.prenet.cz/weblims) enabling referring physicians to access genetic test results in real time as soon as PRENET's laboratory releases them. Includes search functionality and reporting; access setup coordinated through PRENET.
• Childbirth Preparation Courses (Předporodní kurzy) Six-week childbirth preparation course with 2-hour sessions (max. 7 mothers per course) covering labor process, breathing techniques, newborn care, breastfeeding, and infant first aid. The final session is partner-inclusive and covers neonatal resuscitation. Priced at 3,500 CZK and held at 17. listopadu 342, Pardubice.

Quantifiable outcome

• NIPT detects 99% of Down syndrome and Edwards syndrome cases
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, minor and moderate.

• GHC Genetics, s.r.o.coreTechnology or IntegrationSister company providing genetic testing services at Prague location. Part of the same corporate group as Laboratoře lékařské genetiky. Prague genetic tests are performed by GHC Genetics.
• GenePlanetcoreTechnology or IntegrationExternal laboratory partner for NIPT (Non-Invasive Prenatal Testing) services. NIPT tests (NIPT Rh, PLUS, PRO, PREMIUM, TWINS variants) are processed in GenePlanet laboratories.
• STAPROcoreTechnology or IntegrationProvider of OpenLIMS laboratory information system used by PRENET since August 2022 for laboratory operations management.
• ASGENT (asgent.org)minorStrategic or Co-development PartnerListed as a partner organization, specific collaboration details not specified in available content.
• ÚPMD - Ústav pro péči o matku a dítě (upmd.cz)moderateStrategic or Co-development PartnerPartner healthcare institution specializing in mother and child care. Collaboration in prenatal diagnostics and genetic testing services.
• FN Motol (Fakultní nemocnice v Motole)moderateStrategic or Co-development PartnerAcademic medical center partnership. Doc. MUDr. Viktor Tomek Ph.D. serves as Head of Echocardiography and Prenatal Cardiology at FN Motol while consulting at PRENET.
• Meta Platforms Ireland LimitedminorGTM or Marketing PartnerFacebook/Meta pixel used for website analytics and targeted advertising. Meta pixel tracks user actions on website for ad optimization and advanced matching purposes.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• GenePlanet: European (Slovenia-based) NIPT and genetic testing laboratory that is PRENET's NIPT processing partner and a direct competitor in the Central European NIPT market. Comparable in NIPT product structure, twin pregnancy offerings, and premium self-pay positioning.
• Repromeda: Czech reproductive medicine and genetics clinic offering IVF, PGT, prenatal genetics, and reproductive immunology. Closely comparable to PRENET in Czech women's reproductive health and genetics service scope, though with stronger IVF emphasis.
• Agellab: Czech genetic diagnostics laboratory offering cytogenetics, molecular genetics, prenatal diagnostics, and hereditary cancer testing. Directly comparable as a Czech genetics laboratory competitor with similar accreditation profile and test menu.
• GHC Genetics: Czech genetic testing laboratory operating as PRENET's sister company within the same corporate group, performing genetic tests for PRENET's Prague branch. Directly comparable in service portfolio (cytogenetics, molecular genetics, prenatal genetics) and Czech market focus.
• Gennet: Czech fertility clinic network (Prague, Brno) offering IVF, reproductive genetics, and prenatal diagnostics. Comparable as a Czech private women's reproductive health provider with integrated lab capabilities and similar patient demographic.

Broad incumbents

• Natera: US-listed genetic testing company with a European footprint offering Panorama NIPT, Empower hereditary cancer screening, and Signatera oncology. Comparable as a specialty NIPT and hereditary genetics competitor with overlapping self-pay and physician-channel products.
• Centogene: Germany-based rare disease and genetic diagnostics company offering carrier screening, NIPT, and hereditary cancer panels. Comparable as a specialized European genetics player with overlapping test menu (BRCA, CZECANCA-equivalent panels, reproductive genetics).
• Synlab: Pan-European medical diagnostics network with a large Czech operation covering routine and specialty genetic testing. Comparable as a broader incumbent offering overlapping capabilities (prenatal screening, hereditary cancer, cytogenetics) but as part of a much wider lab portfolio.
• Unilabs: Large European diagnostics provider with Central European presence offering clinical genetics and prenatal testing. Comparable as a broad incumbent entering the same specialty testing categories PRENET serves, though at materially greater scale.

Regional players

• GENPRO: Czech provider of preventive genetic testing and nutrigenomics services with direct-to-consumer emphasis. Comparable as a regional Czech player in self-pay preventive genetics, though more focused on lifestyle/consumer genetics than PRENET's clinical prenatal focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laborato%C5%99e-l%C3%A9ka%C5%99sk%C3%A9-genetiky

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRENET